Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Takeda Oncology.

EGFR Exon 20 NSCLC Tumor Board: Aligning Patient and Evidence to Inform Treatment Decisions in Real World Care Scenarios

Release Date: June 29, 2021
Expiration Date: June 29, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in non–small cell lung cancer (NSCLC). Of the 10% to 20% of lung cancer diagnoses expected to be EGFR mutation–positive, a significant subset of patients do not respond to clinically available EGFR tyrosine kinase inhibitors, particularly those harboring an EGFR exon 20 insertion mutation. Given the challenges in the treatment of patients with nonclassical EGFR mutations, it is essential for clinicians to be aware of optimal testing strategies for patients with NSCLC.

This CME activity helps oncology health care professionals who participate in the multidisciplinary treatment of patients with lung cancer to develop expert competence in molecular testing and management of patients with EGFR exon 20 insertion mutations. The faculty provide a review of the latest clinical data in the real-world context of a tumor board discussion. Topics comprise strategies to optimize identification of EGFR exon 20 insertions including interpretation of molecular results; current and emerging treatment options; and appropriate clinical trials available to this molecular subset of patients.

This educational activity is an archive of the live virtual symposium held on June 9, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, pathologists, histologists, pulmonologists, and other health care professionals who treat or manage patients with non–small cell lung carcinoma (NSCLC). Nurse practitioners, nurses, and physician assistants involved in the treatment and management of patients with lung cancer are also invited to participate.


Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the impact of EGFR exon 20 insertion mutations on tumor biology and in the context of outcomes, compared with other EGFR mutational subtypes.
  • Outline molecular testing strategies and their optimal timing for patients with NSCLC and EGFR exon 20 insertions along the disease continuum.
  • Assess safety and effi cacy results from clinical trials that evaluated treatment among patients with advanced NSCLC and EGFR exon 20 insertions.
  • Integrate emerging safety and effi cacy data for EGFR exon 20 insertion–directed systemic therapy into clinical scenarios for patients with NSCLC.

Program Co-Chairs

Rodolfo Bordoni, MD
Rodolfo Bordoni, MD
Director of the Clinical Research
Georgia Cancer Specialists
Atlanta, GA

Disclosures: Consultant: NeoGenomics, Guardant; Speaker’s Bureau: Guardant, Merck, AstrasZeneca, NeoGenomics.

Hossein Borghaei, DO, MS
Hossein Borghaei, DO, MS
Professor and Chief, Thoracic Medical Oncology
Codirector, Immune Monitoring Facility
Coleader, Molecular Therapeutics Program
Gloria and Edmund M. Dunn Chair in Thoracic Surgical Oncology
Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA

Disclosures: Grant Research Support: Millennium Pharmaceuticals, Inc, Bristol Meyers Squibb, Lilly; Consultant: Bristol Meyers Squibb; Lilly; Genentech, Inc; Celgene Corp; Pfizer; Merck; EMD-Serono; Boehringer Ingelheim; AstraZeneca; Novartis; Genmab A/S; Regeneron Pharmaceuticals, Inc; BioNTech SE; Cantargia AB; Amgen Inc; Abbvie Inc; Axiom Pharmaceuticals Inc; PharmaMar S.A.; Takeda; HUYA Bioscience International, LLC; GLG Pharma Corp; Daiichi Sankyo Co, Ltd.; Stock/shareholder: Rgenix, Inc; Sonnet BioTherapeutics, Inc; NucleAI (Scientific Advisory Board); Other: DSMB: Incyte Corp;Takeda; University of Pennsylvania.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By